Phospholipase A2 Group III and Group X Have Opposing Associations with Prognosis in Colorectal Cancer
Kazama, S.; Kitayama, J.; Hiyoshi, M.; Taketomi, Y.; Murakami, M.; Nishikawa, T.; Tanaka, T.; Tanaka, J.; Kiyomatsu, T.; Kawai, K.; Hata, K.; Yamaguchi, H.; Nozawa, H.; Ishihara, S.; Sunami, E.; Watanabe, T.
Anticancer Research 35(5): 2983-2990
2015
ISSN/ISBN: 0250-7005 PMID: 25964585 Document Number: 684238
Although secretory phospholipase A2 (sPLA2) has been shown to be involved in various biological processes, its specific roles in sub-types of cancer development remain to be elucidated. We examined the expression of sPLA2 group III (GIII) in 142 patients with colorectal cancer using immunohistochemistry, and its correlation with clinicopathological features and outcomes. In addition, we examined the co-expression of sPLA2GIII and sPLA2GX using serial tissue sections to clarify the roles of both proteins in colorectal carcinogenesis. In 66 cases, diffuse staining of sPLA2GIII was seen; this was defined as the group with high expression. High expression was associated with a significantly higher rate of lymph node metastasis (p=0.02) and poorer survival (p=0.03) compared with low expression. Patients with low sPLA2GIII and high sPLA2GX expression had a significantly higher survival rate than those with high sPLA2GIII and low sPLA2GX expression (p=0.038). sPLA2GIII expression may be used as a risk factor for lymph node metastasis and a prognostic marker in colorectal cancer. In addition, sPLA2GIII and sPLA2GX may play opposing roles in colorectal carcinogenesis.